Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ENTA NASDAQ:INBX NASDAQ:MLTX NASDAQ:MRVI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeENTAEnanta Pharmaceuticals$11.40+0.4%$13.49$6.43▼$17.15$332.09M0.97188,842 shs8,384 shsINBXInhibrx Biosciences$88.89-0.2%$98.73$13.92▼$155.29$1.30B3.31318,991 shs90,371 shsMLTXMoonLake Immunotherapeutics$17.65-0.9%$17.75$5.95▼$62.75$1.30B1.041.54 million shs74,631 shsMRVIMaravai LifeSciences$5.25+2.8%$3.92$1.99▼$5.28$1.35B0.721.87 million shs470,784 shs7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceENTAEnanta Pharmaceuticals+2.53%-5.65%-26.01%-19.90%+51.33%INBXInhibrx Biosciences-0.03%-4.84%-33.68%+21.22%+519.18%MLTXMoonLake Immunotherapeutics-1.11%-0.39%+4.34%-0.22%-61.82%MRVIMaravai LifeSciences+1.19%+5.59%+5.15%+43.66%+123.68%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeENTAEnanta Pharmaceuticals$11.40+0.4%$13.49$6.43▼$17.15$332.09M0.97188,842 shs8,384 shsINBXInhibrx Biosciences$88.89-0.2%$98.73$13.92▼$155.29$1.30B3.31318,991 shs90,371 shsMLTXMoonLake Immunotherapeutics$17.65-0.9%$17.75$5.95▼$62.75$1.30B1.041.54 million shs74,631 shsMRVIMaravai LifeSciences$5.25+2.8%$3.92$1.99▼$5.28$1.35B0.721.87 million shs470,784 shs7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceENTAEnanta Pharmaceuticals+2.53%-5.65%-26.01%-19.90%+51.33%INBXInhibrx Biosciences-0.03%-4.84%-33.68%+21.22%+519.18%MLTXMoonLake Immunotherapeutics-1.11%-0.39%+4.34%-0.22%-61.82%MRVIMaravai LifeSciences+1.19%+5.59%+5.15%+43.66%+123.68%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceENTAEnanta Pharmaceuticals 2.75Moderate Buy$20.2979.04% UpsideINBXInhibrx Biosciences 2.33Hold$150.0062.44% UpsideMLTXMoonLake Immunotherapeutics 2.38Hold$23.8533.85% UpsideMRVIMaravai LifeSciences 2.20Hold$5.507.00% UpsideCurrent Analyst Ratings BreakdownLatest ENTA, MRVI, MLTX, and INBX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/9/2026MLTXMoonLake Immunotherapeutics BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$30.006/8/2026MLTXMoonLake Immunotherapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$45.006/3/2026MRVIMaravai LifeSciences UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingReduce5/29/2026MRVIMaravai LifeSciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)5/13/2026MRVIMaravai LifeSciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/12/2026MLTXMoonLake Immunotherapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)5/12/2026MLTXMoonLake Immunotherapeutics Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$25.00 ➝ $30.005/11/2026MLTXMoonLake Immunotherapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$40.00 ➝ $45.005/8/2026MRVIMaravai LifeSciences Deutsche Bank AktiengesellschaftSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$6.005/8/2026MRVIMaravai LifeSciences Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$4.50 ➝ $5.504/24/2026INBXInhibrx Biosciences Lifesci CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy(Data available from 6/10/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookENTAEnanta Pharmaceuticals$65.32M5.04N/AN/A$3.03 per share3.74INBXInhibrx Biosciences$1.30M1,042.02N/AN/A$0.55 per share167.89MLTXMoonLake ImmunotherapeuticsN/AN/AN/AN/A$4.27 per shareN/AMRVIMaravai LifeSciences$185.74M7.14$0.43 per share12.04$1.46 per share3.52Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateENTAEnanta Pharmaceuticals-$81.89M-$2.59N/AN/AN/A-89.56%-64.04%-20.22%8/10/2026 (Confirmed)INBXInhibrx Biosciences-$140.05M-$8.39N/AN/AN/AN/A-563.90%-72.32%8/12/2026 (Estimated)MLTXMoonLake Immunotherapeutics-$227.32M-$3.87N/AN/AN/AN/A-85.15%-60.52%8/4/2026 (Estimated)MRVIMaravai LifeSciences-$130.77M-$0.71N/AN/AN/A-51.07%-17.87%-9.08%8/10/2026 (Estimated)Latest ENTA, MRVI, MLTX, and INBX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2026Q1 2026INBXInhibrx Biosciences-$1.6750-$2.15-$0.4750-$2.15N/AN/A5/11/2026Q2 2026ENTAEnanta Pharmaceuticals-$0.46-$0.45+$0.01-$0.45$17.03 million$17.16 million5/11/2026Q1 2026MLTXMoonLake Immunotherapeutics-$0.91-$0.98-$0.07-$0.98N/AN/A5/7/2026Q1 2026MRVIMaravai LifeSciences-$0.05$0.01+$0.06-$0.02$53.00 million$65.84 million3/19/2026Q4 2025INBXInhibrx Biosciences-$2.08-$2.11-$0.03-$2.11N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthENTAEnanta PharmaceuticalsN/AN/AN/AN/AN/AINBXInhibrx BiosciencesN/AN/AN/AN/AN/AMLTXMoonLake ImmunotherapeuticsN/AN/AN/AN/AN/AMRVIMaravai LifeSciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioENTAEnanta PharmaceuticalsN/A3.843.84INBXInhibrx Biosciences12.586.466.46MLTXMoonLake Immunotherapeutics0.398.608.60MRVIMaravai LifeSciences0.725.914.96Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipENTAEnanta Pharmaceuticals94.99%INBXInhibrx Biosciences82.46%MLTXMoonLake Immunotherapeutics93.85%MRVIMaravai LifeSciences50.25%Insider OwnershipCompanyInsider OwnershipENTAEnanta Pharmaceuticals11.48%INBXInhibrx Biosciences18.26%MLTXMoonLake Immunotherapeutics12.05%MRVIMaravai LifeSciences2.49%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableENTAEnanta Pharmaceuticals16029.08 million25.74 millionOptionableINBXInhibrx Biosciences16614.67 million11.99 millionOptionableMLTXMoonLake Immunotherapeutics273.61 million64.74 millionOptionableMRVIMaravai LifeSciences610258.19 million251.76 millionOptionableENTA, MRVI, MLTX, and INBX HeadlinesRecent News About These CompaniesThis is why Maravai Lifesciences Holdings Inc. (MRVI) is a Top penny Stock in the Top Investors PortfolioJune 7 at 7:16 PM | finance.yahoo.comMaravai LifeSciences (NASDAQ:MRVI) & Senestech (NASDAQ:SNES) Head-To-Head ReviewJune 6, 2026 | americanbankingnews.comMaravai LifeSciences Announces Refinancing of Credit Agreement, Extending Maturity to 2032June 3, 2026 | businesswire.comMaravai Lifesciences Shareholders Back Board, Pay, AuditorMay 29, 2026 | tipranks.comMaravai LifeSciences To Attend The Jefferies Global Healthcare ConferenceMay 18, 2026 | businesswire.comMaravai LifeSciences: Better Earnings Drive Gains That Ought To Be SustainableMay 18, 2026 | seekingalpha.comHow The Maravai LifeSciences (MRVI) Narrative Is Shifting With New Targets And 2026 GuidanceMay 16, 2026 | finance.yahoo.com457,707 Shares in Maravai LifeSciences Holdings, Inc. $MRVI Purchased by Brummer Multi Strategy ABMay 11, 2026 | marketbeat.comMaravai LifeSciences Holdings, Inc. (MRVI) Q1 2026 Earnings Call TranscriptMay 10, 2026 | seekingalpha.comMaravai (MRVI) Q1 2026 Earnings TranscriptMay 9, 2026 | finance.yahoo.comMaravai LifeSciences Reports First Quarter 2026 Financial ResultsMay 7, 2026 | finance.yahoo.comMaravai LifeSciences Holdings, Inc. 2026 Q1 - Results - Earnings Call PresentationMay 7, 2026 | seekingalpha.comMaravai LifeSciences Holdings, Inc. (MRVI) Tops Q1 Earnings and Revenue EstimatesMay 7, 2026 | zacks.comAll You Need to Know About Maravai LifeSciences (MRVI) Rating Upgrade to BuyMay 6, 2026 | zacks.comBaxter International (BAX) Tops Q1 Earnings and Revenue EstimatesApril 30, 2026 | zacks.comMaravai LifeSciences To Host Earnings Conference Call on Thursday, May 7, 2026April 21, 2026 | timesargus.comTMaravai LifeSciences (MRVI) carrying moderately bullish sentiment despite options-linked volatilityApril 14, 2026 | msn.comHow Maravai LifeSciences (MRVI) Q4 Results Are Shaping A Cautious Valuation NarrativeApril 13, 2026 | finance.yahoo.comMaravai LifeSciences Holdings Inc.April 12, 2026 | barrons.comHow The Maravai LifeSciences (MRVI) Story Is Shifting As Analysts Rework Fair Value TargetsMarch 30, 2026 | finance.yahoo.comMaravai targets $200M–$210M 2026 revenue as restructuring drives early EBITDA turnaroundFebruary 26, 2026 | seekingalpha.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesRocket Lab Is Down 24% From Its 52-Week High—Pullback or Problem?By Ryan Hasson | June 4, 20262 Software Stocks Turning AI Fears Into Fundamental GainsBy Dan Schmidt | May 21, 2026Drone Stocks Soar As Pentagon Considers Funding, Including a Trump-Linked NameBy Leo Miller | June 1, 2026The Pentagon's AI Pivot Supercharges Defense StocksBy Jeffrey Neal Johnson | May 19, 20263 Dividend Kings That Earn Their Crown Every QuarterBy Chris Markoch | May 31, 2026ENTA, MRVI, MLTX, and INBX Company DescriptionsEnanta Pharmaceuticals NASDAQ:ENTA$11.40 +0.05 (+0.40%) As of 10:42 AM Eastern This is a fair market value price provided by Massive. Learn more.Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. The company has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. Enanta Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in Watertown, Massachusetts.Inhibrx Biosciences NASDAQ:INBX$88.88 -0.22 (-0.24%) As of 10:42 AM Eastern This is a fair market value price provided by Massive. Learn more.Inhibrx, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also develops INBRX-109, a tetravalent therapeutic candidate targeting death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, colorectal cancer, ewing sarcoma, and pancreatic adenocarcinoma; and INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company has license and collaboration agreements with 2seventy bio, Inc. and Bristol-Myers Squibb Company. Inhibrx, Inc. was incorporated in 2009 and is headquartered in La Jolla, California.MoonLake Immunotherapeutics NASDAQ:MLTX$17.64 -0.16 (-0.87%) As of 10:43 AM Eastern This is a fair market value price provided by Massive. Learn more.MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.Maravai LifeSciences NASDAQ:MRVI$5.24 +0.15 (+2.84%) As of 10:42 AM Eastern This is a fair market value price provided by Massive. Learn more.Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as custom enzyme development and manufacturing and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody, and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, viral clearance prediction kits, and custom services. The company serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. The company was incorporated in 2020 and is headquartered in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas FuelCell Energy Just Got a Wake-Up Call From Wall Street Uranium Energy Corp Melts Down—Nuclear Opportunity at Hand Corning Is Paving AI's Future With Glass Short Sellers Are Piling Into Wingstop, But Analysts See Big Upside Optical Cable Corporation: Strong Earnings, But Hurdles Remain The J.M. Smucker Company’s Dividend: Too Sweet to Ignore? Why's Amazon Suddenly Lagging the S&P 500, and Is It a Warning? Apple's Siri AI Was Finally Announced, So Why Is the Stock Tanking? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
